Site updated at Wednesday, 22 June 2016

Living with Dementia

Transdermal Rivastigmine

Drug Patch Gets OK for Severe Alzheimer’s

The FDA has expanded the indication for transdermal rivastigmine to include patients with severe Alzheimer’s disease.

The approval means that the transdermal agent is indicated for use in any Alzheimer’s patient, irrespective of disease stage or severity. The expanded indication is the first of its type for any Alzheimer’s drug, according to a statement… Drug Patch Gets OK for Severe Alzheimer’s   

Alzheimer’s Disease

structural changes1 - specific sugar molecules1 - igf resistance1 - frontotemporal lobar degeneration4 - encephalopathy-alcoholic10 - foolishness1 - early alzheimer's damage1 - dementia alliance1 - mediterranean diet1 - epilepsy1 - hallucinations1 - physical reality1 - problems with speech1 - vitamin b-11 - caffeine2 - tasigna1 - brain tissue1 - huntington disease2 - diagnosis of ad1 - carus1 - cognitive ability1 - alzheimer's brain1 - icd-101 - huntington's disease8 - cognitive skills2 - memory problems3 - ipscs1 - senile atrophy and aphasia1 - memory disorder1 - tau proteins1 -